NLRP3-CAMKⅡ-IRE-1α通路激活诱导氧化应激增强对糖尿病大鼠心室重构的影响

doi:10.11958/20230012

天津医药 ›› 2023, Vol. 51 ›› Issue (6): 580-585.doi: 10.11958/20230012

NLRP3-CAMKⅡ-IRE-1α通路激活诱导氧化应激增强对糖尿病大鼠心室重构的影响

周梦竹(), 张海凤, 张雪, 张跃, 程立君, 刘彤, 刘长乐

天津市心血管病离子与分子机能重点实验室，天津医科大学第二医院心脏科，天津心脏病学研究所（邮编300211）

收稿日期:2023-01-03 修回日期:2023-02-27 出版日期:2023-06-15 发布日期:2023-06-20
通讯作者: ^△E-mail：lcl1979_2001@163.com
作者简介:周梦竹（1995），女，硕士在读，主要从事高血压、糖尿病心肌病方面研究。E-mail：mengzhuzhou1995@163.com
基金资助:
国家自然科学基金资助项目(82100342);天津市自然科学基金项目(15JCQNJC10200);天津市自然科学基金项目(21JCYBJC01460);天津市自然科学基金项目(21JCYBJC01740);天津市医学重点学科（专科）项目(TJYXZDXK-029A)

Effect of NLRP3-CAMKⅡ-IRE-1α pathway induced oxidative stress on ventricular remodeling in diabetic rats

ZHOU Mengzhu(), ZHANG Haifeng, ZHANG Xue, ZHANG Yue, CHENG Lijun, LIU Tong, LIU Changle

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China

Received:2023-01-03 Revised:2023-02-27 Published:2023-06-15 Online:2023-06-20
Contact: ^△E-mail：lcl1979_2001@163.com

周梦竹, 张海凤, 张雪, 张跃, 程立君, 刘彤, 刘长乐. NLRP3-CAMKⅡ-IRE-1α通路激活诱导氧化应激增强对糖尿病大鼠心室重构的影响[J]. 天津医药, 2023, 51(6): 580-585.

ZHOU Mengzhu, ZHANG Haifeng, ZHANG Xue, ZHANG Yue, CHENG Lijun, LIU Tong, LIU Changle. Effect of NLRP3-CAMKⅡ-IRE-1α pathway induced oxidative stress on ventricular remodeling in diabetic rats[J]. Tianjin Medical Journal, 2023, 51(6): 580-585.

摘要/Abstract

摘要：

目的探讨核苷酸结合寡聚结构域样受体蛋白3（NLRP3）炎性小体通过钙调素依赖性蛋白激酶Ⅱ（CaMKⅡ）激活肌醇需求激酶-1α（IRE-1α）促进氧化应激增强在糖尿病大鼠心室重构中的作用及机制。方法 36只健康雄性Sprague-Dawley大鼠按随机数字表法分为对照组（CTL组）、糖尿病组（DM组）和糖尿病+格列苯脲组（GLB组），每组12只。大鼠通过单次腹腔注射55 mg/kg链脲佐菌素制备糖尿病模型，GLB组于造模成功后给予NLRP3抑制剂格列苯脲（1.25 mg/kg），连续灌胃8周。CTL组不进行任何干预。8周后记录各组血糖、血压、体质量，计算心室体质量比，测量血流动力学指标；心脏超声检查评估肺动脉血流加速时间、平均肺动脉压、收缩期与舒张期室间隔、心室前壁和心室后壁厚度；心外膜激活映射标测进行心外膜传导速度、绝对不均匀性和不均匀指数测定；采用蛋白免疫印迹检测NLRP3、胱天蛋白酶（caspase）-1、CaMKⅡ、IRE-1α、还原型烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NOX）2、NOX4的蛋白水平；荧光染色法测定活性氧（ROS）含量；HE及Masson染色观察心室组织细胞形态和纤维化。结果与CTL组相比，DM组的血糖升高，心室体质量比增大，收缩期和舒张期室间隔厚度、左心室前壁厚度增加，体质量降低，左、右心室心外膜传导速度减慢，右心室不均匀指数增加，NLRP3、caspase-1、CaMKⅡ、IRE-1α、NOX2和NOX4蛋白表达水平升高，心室肌ROS产生增多，CVF升高（P<0.05），心室肌细胞排列紊乱，纤维化更明显；与DM组比较，GLB组收缩期和舒张期室间隔厚度、左心室前壁厚度降低，左、右心室心外膜传导速度增快，左心室绝对不均匀性和不均匀指数降低，NLRP3、caspase-1、CaMKⅡ、IRE-1α、NOX2和NOX4蛋白表达水平下降，ROS产生减少，CVF降低（P<0.05），心室肌纤维化程度减轻。结论糖尿病大鼠心室肌细胞NLRP3-CAMKⅡ-IRE-1α通路激活，促进氧化应激增强，参与心室重构，GLB可改善此变化。

关键词: 糖尿病, NLR家族, 热蛋白结构域包含蛋白3, 心室重构, 氧化性应激, 内质网应激, 肌醇需求激酶-1α

Abstract:

Objective To explore the role and mechanism of nucleotide-binding domain-like receptor protein 3 (NLRP3) inflammasome in promoting oxidative stress enhancement through triggering calmodulin-dependent protein kinase Ⅱ (CaMKⅡ) to activate inositol demand kinase-1α (IRE-1α) in ventricular remodeling of diabetic rats. Methods Thirty-six healthy male Sprague-Dawley rats were randomly divided into the control group (CTL group), the diabetic group (DM group) and the diabetic + glibenclamide group (GLB group), with 12 rats in each group. Rats were injected 55 mg/kg streptozotocin intraperitoneally to prepare diabetic model. The GLB group was given 1.25 mg/kg GLB, an NLRP3 inhibitor, by gavage for 8 weeks since the successful modeling day. The CTL group received no intervention. After 8 weeks, blood glucose, blood pressure, body mass and ventricular body mass ratio of rats were recorded, and hemodynamic indexes were also measured. Pulmonary artery blood flow acceleration time, mean pulmonary artery pressure, systolic and diastolic ventricular septum, anterior and posterior ventricular wall thickness were evaluated by echocardiography. Epicardial activation mapping was used to measure epicardial conduction velocity, absolute heterogeneity and heterogeneity index. Western blot assay was used to detect NLRP3, caspase-1, CaMK Ⅱ, IRE-1α, niacinamide adenine dinucleotide phosphate (NOX) 2 and NOX4 protein levels. The content of reactive oxygen species (ROS) was determined by fluorescence staining. The morphology and fibrosis of ventricular tissue were observed by HE and Masson staining. Results Compared with the CTL group, blood glucose, ventricular body mass ratio, systolic and diastolic septal thickness, left ventricular anterior wall thickness increased, body mass decreased, left and right ventricular epicardial conduction velocity slowed down, and right ventricular inhomogeneity index increased in the DM group. NLRP3, caspase-1, CaMK Ⅱ, IRE-1α, NOX2 and NOX4 protein expression levels were increased, and ROS production in ventricular muscle and CVF were increased (P<0.05). Myocardial cell arrangement was disordered, and fibrosis was more obvious in the DM group. Compared with the DM group, the thickness of ventricular septum and anterior wall of left ventricle in systolic and diastolic periods were reduced in the GLB group. Compared with the DM group, epicardial conduction velocity of left and right ventricles was increased, and absolute inhomogeneity and inhomogeneity index of left ventricle were decreased in the GLB group. The protein expression levels of NLRP3, caspase-1, CaMKⅡ, IRE-1α, NOX2 and NOX4 were lower than those of the DM group. GLB reduced the production of ROS and CVF, and the ventricular myocardial fibrosis was ameliorated (P<0.05). Conclusion The NLRP3-CAMK Ⅱ-IRE-1α pathway is activated in diabetic rat ventricular myocytes to promote oxidative stress and participates in ventricular remodeling, and GLB can improve this change.

Key words: diabetes mellitus, NLR family, pyrin domain-containing 3 protein, ventricular remodeling, oxidative stress, endoplasmic reticulum stress, IRE-1α

中图分类号:

R541.75，R587.1

图/表 7

参考文献 29

[1]	ZHANG M, SUI W, XING Y, et al. Angiotensin Ⅳ attenuates diabetic cardiomyopathy via suppressing FoxO1-induced excessive autophagy,apoptosis and fibrosis[J]. Theranostics, 2021, 11(18):8624-8639. doi:10.7150/thno.48561.
[2]	MURTAZA G, VIRK H U H, KHALID M, et al. Diabetic cardiomyopathy - A comprehensive updated review[J]. Prog Cardiovasc Dis, 2019, 62(4):315-326. doi:10.1016/j.pcad.2019.03.003.
[3]	ZHANG X, DONG S, JIA Q, et al. The microRNA in ventricular remodeling: the miR-30 family[J]. Biosci Rep, 2019, 39(8):BSR20190788. doi:10.1042/BSR20190788.
[4]	RITCHIE R H, ABEL E D. Basic mechanisms of diabetic heart disease[J]. Circ Res, 2020, 126(11):1501-1525. doi:10.1161/CIRCRESAHA.120.315913.
[5]	HE Y, CHANG Y, PENG Y, et al. Glibenclamide directly prevents neuroinflammation by targeting SUR1-TRPM4-mediated NLRP3 inflammasome activation in microglia[J]. Mol Neurobiol, 2022, 59(10):6590-6607. doi:10.1007/s12035-022-02998-x.
[6]	YANG J, YANG J, HUANG X, et al. Glibenclamide alleviates LPS-induced acute lung injury through NLRP3 inflammasome signaling pathway[J]. Mediators Inflamm, 2022, 2022:8457010. doi:10.1155/2022/8457010.
[7]	ZHAN X, CHENG L, HUO N, et al. Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway[J]. Front Cardiovasc Med, 2022, 9:908037. doi:10.3389/fcvm.2022.908037.
[8]	VAYKSHNORAYTE M A, OVECHKIN A O, AZAROV J E. The effect of diabetes mellitus on the ventricular epicardial activation and repolarization in mice[J]. Physiol Res, 2012, 61(4):363-370. doi:10.33549/physiolres.932245.
[9]	TIAN J H, WU Q, HE Y X, et al. Zonisamide,an antiepileptic drug,alleviates diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress[J]. Acta Pharmacol Sin, 2021, 42(3):393-403. doi:10.1038/s41401-020-0461-z.
[10]	PASSARELLI M, MACHADO U F F. AGEs-induced and endoplasmic reticulum stress/inflammation-mediated regulation of GLUT4 expression and atherogenesis in diabetesmellitus[J]. Cells, 2021, 11(1):104. doi:10.3390/cells11010104.
[11]	MANGAN M S J, OLHAVA E J, ROUSH W R, et al. Targeting the NLRP3 inflammasome in inflammatory diseases[J]. Nat Rev Drug Discov, 2018, 17(9):688. doi:10.1038/nrd.2018.149.
[12]	HUANG Y, XU W, ZHOU R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18(9):2114-2127. doi:10.1038/s41423-021-00740-6.
[13]	WU C, LU W, ZHANG Y, et al. Inflammasome activation triggers blood clotting and host death through pyroptosis[J]. Immunity, 2019, 50(6):1401-1411.e4. doi:10.1016/j.immuni.2019.04.003.
[14]	WU X, LIU Y, TU D, et al. Role of NLRP3-inflammasome/caspase-1/galectin-3 pathway on atrial remodeling in diabetic rabbits[J]. J Cardiovasc Transl Res, 2020, 13(5):731-740. doi:10.1007/s12265-020-09965-8.
[15]	QIU X, WANG Q, HOU L, et al. Inhibition of NLRP3 inflammasome by glibenclamide attenuated dopaminergic neurodegeneration and motor deficits in paraquat and maneb-induced mouse Parkinson's disease model[J]. Toxicol Lett, 2021, 349:1-11. doi:10.1016/j.toxlet.2021.05.008.
[16]	SINGH S, SHAIMA A, AHMAD S, et al. Convergence of fructose-induced NLRP3 activation with oxidative stress and ER stress leading to hepatic steatosis[J]. Inflammation, 2023, 46(1):217-233. doi:10.1007/s10753-022-01727-9.
[17]	DWIVEDI D K, JENA G B. NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress,inflammation,DNA damage and insulin signalling pathway[J]. Naunyn Schmiedebergs Arch Pharmacol, 2020, 393(4):705-716. doi:10.1007/s00210-019-01773-5.
[18]	HEIJMAN J, MUNA A P, VELEVA T, et al. Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation[J]. Circ Res, 2020, 127(8):1036-1055. doi:10.1161/CIRCRESAHA.120.316710.
[19]	NIE J, TA N, LIU L, et al. Activation of CaMKII via ER-stress mediates coxsackievirus B3-induced cardiomyocyte apoptosis[J]. Cell Biol Int, 2020, 44(2):488-498. doi:10.1002/cbin.11249.
[20]	MARCINIAK S J, CHAMBERS J E, RON D. Pharmacological targeting of endoplasmic reticulum stress in disease[J]. Nat Rev Drug Discov, 2022, 21(2):115-140. doi:10.1038/s41573-021-00320-3.
[21]	REN J, BI Y, SOWERS J R, et al. Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases[J]. Nat Rev Cardiol, 2021, 18(7):499-521. doi:10.1038/s41569-021-00511-w.
[22]	HETZ C, ZHANG K, KAUFMAN R J. Mechanisms,regulation and functions of the unfolded protein response[J]. Nat Rev Mol Cell Biol, 2020, 21(8):421-438. doi:10.1038/s41580-020-0250-z.
[23]	WADGAONKAR P, CHEN F. Connections between endoplasmic reticulum stress-associated unfolded protein response,mitochondria,and autophagy in arsenic-induced carcinogenesis[J]. Semin Cancer Biol, 2021, 76:258-266. doi:10.1016/j.semcancer.2021.04.004.
[24]	YARIBEYGI H, LHAF F, SATHYAPALAN T, et al. Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy:Implications for lowering tissue damage[J]. Life Sci, 2019, 231:116538. doi:10.1016/j.lfs.2019.06.013.
[25]	YARIBEYGI H, SATHYAPALAN T, ATKIN S L, et al. Molecular mechanisms linking oxidative stress and diabetes mellitus[J]. Oxid Med Cell Longev, 2020, 2020:8609213. doi:10.1155/2020/8609213.
[26]	IGHODARO O M. Molecular pathways associated with oxidative stress in diabetes mellitus[J]. Biomed Pharmacother, 2018, 108:656-662. doi:10.1016/j.biopha.2018.09.058.
[27]	LIU X, HUSSAIN R, MEHMOOD K, et al. Mitochondrial-endoplasmic reticulum communication-mediated oxidative stress and autophagy[J]. Biomed Res Int, 2022, 2022:6459585. doi:10.1155/2022/6459585.
[28]	POZNYAK A, GRECHKO A V, POGGIO P, et al. The diabetes mellitus-atherosclerosis connection:The role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci, 2020, 21(5):1835. doi:10.3390/ijms21051835.
[29]	ZEESHAN H M, LEE G H, KIM H R, et al. Endoplasmic reticulum stress and associated ROS[J]. Int J Mol Sci, 2016, 17(3):327. doi:10.3390/ijms17030327.

组别		血糖（mmol/L）	体质量（g）		心室体质量比（‰）		收缩压（mmHg）		舒张压（mmHg）		心率（次/min）		肺动脉血流加速时间（ms）
CTL组		7.67±1.32	424.20±33.97		2.93±0.17		119.30±9.37		85.67±7.17		346.50±30.35		32.22±3.16
DM组		27.72±5.73^a	233.20±65.85^a		3.35±0.25^a		126.20±7.94		82.33±9.42		295.20±43.80		29.90±6.87
GLB组		28.33±2.24^a	267.50±68.76^a		3.08±0.12		120.50±10.77		88.17±8.35		346.80±29.71		32.58±4.72
F		62.870^＊＊	18.260^＊＊		7.830^＊＊		0.902		0.735		4.275^＊		0.476
组别	平均肺动脉压（mmHg）			收缩期室间隔厚度（mm）		舒张期室间隔厚度（mm）		收缩期左心室前壁厚度（mm）		舒张期左心室前壁厚度（mm）		收缩期左心室后壁厚度（mm）		舒张期左心室后壁厚度（mm）
CTL组	70.03±1.96			2.69±0.25		1.63±0.24		2.89±0.19		1.76±0.06		2.73±0.42		1.96±0.25
DM组	71.46±4.26			3.41±0.33^a		2.06±0.26^a		3.48±0.42^a		2.39±0.36^a		3.00±0.52		2.11±0.45
GLB组	69.80±2.92			2.62±0.26^b		1.54±0.22^b		2.24±0.32^ab		1.47±0.17^b		2.64±0.41		1.71±0.39
F	0.476			14.350^＊＊		8.134^＊＊		22.140^＊＊		24.910^＊＊		1.039		1.785

组别		血糖（mmol/L）	体质量（g）		心室体质量比（‰）		收缩压（mmHg）		舒张压（mmHg）		心率（次/min）		肺动脉血流加速时间（ms）
CTL组		7.67±1.32	424.20±33.97		2.93±0.17		119.30±9.37		85.67±7.17		346.50±30.35		32.22±3.16
DM组		27.72±5.73^a	233.20±65.85^a		3.35±0.25^a		126.20±7.94		82.33±9.42		295.20±43.80		29.90±6.87
GLB组		28.33±2.24^a	267.50±68.76^a		3.08±0.12		120.50±10.77		88.17±8.35		346.80±29.71		32.58±4.72
F		62.870^＊＊	18.260^＊＊		7.830^＊＊		0.902		0.735		4.275^＊		0.476
组别	平均肺动脉压（mmHg）			收缩期室间隔厚度（mm）		舒张期室间隔厚度（mm）		收缩期左心室前壁厚度（mm）		舒张期左心室前壁厚度（mm）		收缩期左心室后壁厚度（mm）		舒张期左心室后壁厚度（mm）
CTL组	70.03±1.96			2.69±0.25		1.63±0.24		2.89±0.19		1.76±0.06		2.73±0.42		1.96±0.25
DM组	71.46±4.26			3.41±0.33^a		2.06±0.26^a		3.48±0.42^a		2.39±0.36^a		3.00±0.52		2.11±0.45
GLB组	69.80±2.92			2.62±0.26^b		1.54±0.22^b		2.24±0.32^ab		1.47±0.17^b		2.64±0.41		1.71±0.39
F	0.476			14.350^＊＊		8.134^＊＊		22.140^＊＊		24.910^＊＊		1.039		1.785

组别	左心室心外膜传导速度（m/s）			左心室绝对不均匀性		左心室不均匀指数
CTL组	1.05±0.27			2.25±0.23		1.66±0.19
DM组	0.52±0.24^a			4.40±2.21		2.56±0.89
GLB组	1.08±0.29^b			1.68±0.20^b		1.49±0.20^b
F	7.066^＊＊			6.230^＊		5.635^＊
组别		右心室心外膜传导速度（m/s）	右心室绝对不均匀性		右心室不均匀指数
CTL组		0.87±0.20	2.32±0.47		1.38±0.13
DM组		0.58±0.15^a	4.68±3.09		2.01±0.43^a
GLB组		1.09±0.16^b	2.39±0.17		1.65±0.35
F		11.620^＊＊	2.759		4.620^＊

组别	左心室心外膜传导速度（m/s）			左心室绝对不均匀性		左心室不均匀指数
CTL组	1.05±0.27			2.25±0.23		1.66±0.19
DM组	0.52±0.24^a			4.40±2.21		2.56±0.89
GLB组	1.08±0.29^b			1.68±0.20^b		1.49±0.20^b
F	7.066^＊＊			6.230^＊		5.635^＊
组别		右心室心外膜传导速度（m/s）	右心室绝对不均匀性		右心室不均匀指数
CTL组		0.87±0.20	2.32±0.47		1.38±0.13
DM组		0.58±0.15^a	4.68±3.09		2.01±0.43^a
GLB组		1.09±0.16^b	2.39±0.17		1.65±0.35
F		11.620^＊＊	2.759		4.620^＊

组别	NLRP3	caspase-1	CaMKⅡ
CTL组	0.80±0.27	0.41±0.19	1.17±0.16
DM组	1.26±0.33^a	0.81±0.10^a	1.50±0.28^a
GLB组	0.81±0.18^b	0.36±0.20^b	1.12±0.07^b
F	5.814^＊	12.320^＊＊	7.092^＊＊
组别	IRE-1α	NOX2	NOX4
CTL组	0.28±0.09	1.15±0.34	0.92±0.22
DM组	0.56±0.13^a	1.93±0.45^a	1.60±0.21^a
GLB组	0.34±0.10^b	1.25±0.25^b	0.92±0.21^b
F	10.960^＊＊	8.459^＊＊	20.000^＊＊

NLRP3-CAMKⅡ-IRE-1α通路激活诱导氧化应激增强对糖尿病大鼠心室重构的影响

Effect of NLRP3-CAMKⅡ-IRE-1α pathway induced oxidative stress on ventricular remodeling in diabetic rats

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 7

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王欣爽, 安亚娟, 管秀菊, 李娇, 刘玥, 魏丽萍, 齐新. 异甘草酸镁改善顺铂诱导的大鼠心肌损伤[J]. 天津医药, 2024, 52(8): 809-814.
[2]	林峰, 陈铃雄, 刘羽, 张旭明, 尹志达, 林坛辉, 刘尊荣. 紫杉醇涂层球囊治疗2型糖尿病膝下动脉严重病变患者发生远期再狭窄预测模型的构建[J]. 天津医药, 2024, 52(8): 830-834.
[3]	马良, 胡立影, 石羽, 龙刚. 光学相干断层扫描血管成像技术在慢性肾脏病临床评估中的应用进展[J]. 天津医药, 2024, 52(8): 882-887.
[4]	侯维玲, 乔云阳, 吴小芸, 施会敏, 曲高婷, 张爱青. 锌指蛋白281抑制高糖诱导的肾小管上皮细胞上皮间质转化和细胞外基质合成[J]. 天津医药, 2024, 52(7): 720-726.
[5]	钟敏, 施震, 周劲松, 李晋杰. GABA信号通路对脓毒症大鼠急性肺损伤内质网应激和线粒体自噬的影响[J]. 天津医药, 2024, 52(7): 733-737.
[6]	王娴, 刘霞明, 陈曼玉, 赵君, 王立东. 基于机器学习对2型糖尿病肾病预测模型的构建及验证[J]. 天津医药, 2024, 52(7): 775-780.
[7]	夏雨薇, 乔云阳, 刘雪薇, 施会敏, 曲高婷, 张爱青, 甘卫华. tRF-1:30对高糖诱导的肾小管上皮细胞炎性因子表达的影响[J]. 天津医药, 2024, 52(6): 561-566.
[8]	吴波, 朱卓农, 郑丽娟, 陈俊如. 苦参碱对特应性皮炎炎症、氧化应激和伤口愈合的影响[J]. 天津医药, 2024, 52(6): 566-571.
[9]	陈芋洁, 黄霞, 邓铂林, 贾文文. 金合欢素调节Hippo信号通路对糖尿病视网膜病变大鼠血管生成的影响[J]. 天津医药, 2024, 52(6): 578-583.
[10]	王俊懿, 李宸, 吴昕岳, 丁心语, 万春晓. 早期运动干预对脑缺血大鼠脑神经髓鞘的影响及机制研究[J]. 天津医药, 2024, 52(6): 589-594.
[11]	蒋韬, 程红艳, 吴琼. 棕矢车菊素调节SDF-1α/CXCR4信号通路对妊娠糖尿病大鼠炎症反应的影响[J]. 天津医药, 2024, 52(6): 594-598.
[12]	常鸿, 张科伟, 徐静, 崔晓敏, 杨菲菲. 血清HbA1c、Alarin及Ficolin-3水平对妊娠期糖尿病患者妊娠结局的预测价值[J]. 天津医药, 2024, 52(6): 625-629.
[13]	黎敏, 龚坚, 吴伟伟, 刘巧. Nrf2/HO-1通路在银屑病中作用的研究进展[J]. 天津医药, 2024, 52(5): 552-556.
[14]	黄玉, 贺蕊莹, 刘森, 陈开元, 李美运, 程键晔, 武艳. 小球藻提取物促进糖尿病小鼠皮肤创面愈合的作用研究[J]. 天津医药, 2024, 52(4): 337-345.
[15]	王月, 权兴苗, 王玉, 宋春侠, 邵月, 徐立伟. 益气升清方调节HIF-1α/NLRP3信号通路对缺血性脑卒中大鼠神经元焦亡的影响[J]. 天津医药, 2024, 52(4): 350-355.